Igor Puzanov, MD

His role as a Clinical Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Professor of Medicine and Director of Early Phase Clinical Trials Program in the Department of Medicine at Roswell Park Comprehensive Cancer Center, He is developing novel therapies for patients with cancer. This includes clinical trials from the early pre-clinical phase through phase I/II/III with emphasis on a combination of immune and targeted agents, novel drug design, including histology-agnostic trial development of targeted therapies. He also provides advice on regulatory requirements and necessary steps associated with advancing drugs, devices, and imaging agents toward clinical trials in patients.

In his professional career, I have focused both on developing precision medicine agents as well as immunotherapies. In the first-in-human trial of PLX4032/vemurafenib, our team has provided critical PK/PD data that led to the first in class/ first in human FDA-approved BRAF inhibitor. His interest and expertise in immunotherapy started in the early 1990s with animal models of IL-2 and IL-15 cytokines and natural killer cell development, continued with high dose IL-2 studies, and subsequently Phase I-III trials with both CTLA-4 and PD1/PDL-1 checkpoint inhibitors. Our team was instrumental in the development of talimogene laherparepvec, the first in human oncolytic virus therapy for patients with melanoma. Recently, we have explored immunotherapy combinations with targeted agents as well as combinations of oncolytic viruses with checkpoint inhibitors.

Our work was instrumental in several FDA approvals of breakthrough anti-cancer drugs (vemurafenib, dabrafenib+trametinib, vemurafenib+cobimetinib, pembrolizumab, talimogene laherparepvec) and resulted in almost 100 manuscripts, including New England Journal of Medicine, Lancet, Journal of Clinical Oncology, JAMA, Nature. I am a member of American Society of Medical Oncology, Society of Immunotherapy in Cancer, ACP, AACR and Society of Melanoma Research and serve as an editor and reviewer for several peer reviewed journals.